

Issuer/Manager	THE TRENDLINES GROUP LTD.
Securities	THE TRENDLINES GROUP LTD. – IL0011328858 – 42T
Stapled Security	No

Announcement Title	General Announcement
Date & Time of Broadcast	19-Apr-2016 07:12:56
Status	New
Announcement Subtitle	Trend lines Annual General Meeting Presentation (April 2016)
Announcement Reference	SG1604190TH RBR5D
Submitted By (Co./Ind. Name)	Yosef Ron
Designation	Joint Company Secretary
Description	<p>The Trend lines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the Sponsor").</p> <p>This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.</p> <p>This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.</p> <p>The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.</p>

Attachments	Trendlines AGM Presentation - April 2016
-------------	--



Creating & Developing Companies To Improve the Human Condition



Annual General Meeting

19 April 2016

Legal Disclaimer

IMPORTANT NOTICE

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Trendlines: Innovation Commercialization

The Trendlines Group invents, discovers, invests in, and incubates, life science companies in the fields of medical and agricultural technologies.



Israeli Government-Franchised Incubators
Invest in life sciences companies



Internal Innovation Center
Invents and develops technologies to address unmet market needs

More Than 500 Opportunities Reviewed Annually

Sources of Deal Flow

Israel, United States; expanding to Singapore, Germany, China

- Entrepreneurs
- Inventors
- Universities and research institutions
- Needs identified by industry partners

We Look For

- Leaders with passion and commitment
- Unmet needs
- Unique, innovative technologies
- Market potential



Trendlines: From Seed to Success at High Speed



Trendlines: Financial Highlights


(US\$ 000)

	FY2012	FY2013	FY2014	FY2015
Total Portfolio Fair Value*		74,639	77,494	85,776
Total Income	13,768	29,707	8,553	9,939
Non-GAAP Total Expenses before non-recurring, non-cash item	5,158	6,798	11,408	7,938
Non-GAAP Income/(Loss) before income tax and non-recurring, non-cash item	8,610	22,909	(2,855)	2,001
Non-recurring, non-cash item**				3,775
Income/(Loss) before income taxes	8,610	22,909	(2,855)	(1,774)
Earnings per share (US\$)	0.021	0.054	(0.01)	(0.01)

* Includes fair market value of assets carried at equity value


** Non-cash item: One-time discount on conversion of pre-IPO RCL

Trendlines: Value Creation



* Includes fair market value of assets carried at equity value

Trendlines: Consistently Building Value



* Includes fair market value of assets carried at equity value

Trendlines' Recent Developments

- Bayer AG and Trendlines form Bayer Trendlines Agtech Innovation Fund with \$US10 million investment from Bayer
- Definitive collaboration agreement with B. Braun Melsungen AG
- Trendlines Labs collaboration framework agreement with a Japanese multinational medical device company
- Trendlines Labs expands business with U.S. multinational medical device company
- Portfolio company Saturas receives investment of ~US\$1 million
- Three portfolio companies have engaged investment banks to explore exit possibilities

Trendlines and Israel's Office of the Chief Scientist (OCS)

Trendlines Medical received new 8-year license in January 2016 from OCS.
Agtech incubator license expires in June 2016.

Single Israeli Government license allows us to:

- Continue developing existing agritech portfolio companies
- Continue to invest in new agtech companies through —
 - existing incubator license held by Trendlines Medical, if request approved
 - other OCS funding programs

Our Business Strategies

Follow-On Investments in Portfolio Companies

- Accelerate portfolio company development
- Demonstrate support and confidence
- Limit dilution

Expansion into New Markets

Exploring international opportunities, including in Singapore, Germany, and China

Expansion of Trendlines Labs

- Invest in selected technologies to accelerate market entry
- Intensify marketing and business development efforts
- Establish companies from Trendlines Labs' inventions

Intense Support/Increase Number of Portfolio Companies

- Create and develop companies to improve the human condition
- Increase number of portfolio companies by 50% over three years

Highlights From the DBS Vickers Reports

- Strong track record of raising follow-on funding for 75% of portfolio companies and successful sale of 5 portfolio companies or their assets since 2011
- Strong growth prospects in medtech and agtech
 - Aging population and growing demand for sophisticated medical devices
 - Rising global demand for food and water stress
- One year target price of S\$0.28 based on FY16F P/B of 1.1x (versus selected peers trading at 1.3x) and an estimated book value per share of S\$0.256 in FY16F
- No material loss on losing the Agtech license
- Investors should focus on potential exit opportunities in 2016, target price maintained
- Main risks cited:
 - Volatile earnings
 - If there are no exits from existing investments

* Source: DBS initiation report on The Trendlines Group, 11 February 2016 and Flash Note on 17 March 2016

Trendlines: Traded Peer Group & Industry Comparables



As at 13 April 2016	SGD
Last price	0.220
IPO price	0.330
52wk high	0.395
52wk low	0.133
Market cap	109.3 million
Shares outstanding	508.8 million

Price to Portfolio (FMV)*	
Allied Minds (LSE:ALM)	2.40
Imperial Innovations (AIM:IVO)	1.73
IP Group (LSE:IPO)	1.65
PureTech Health (LSE:PRTC)	<u>1.52</u>
Average Price to Portfolio	<u>1.82</u>
Trendlines Price to Portfolio	<u>0.93</u>

*Based on market cap at 13 April 2016, divided by last available portfolio value
Peer Group as per DBS Vickers report 11 February 2016

Thank You!



Medical • Agtech • Labs

+972.72.260.7000 | www.trendlines.com



Todd Dollinger, Chairman & CEO

todd@trendlines.com

Steve Rhodes, Chairman & CEO

steve@trendlines.com